This company profile has not been updated since May 2022, when Comera Life Sciences completed its reverse merger with OTR Acquisition to form Comera Life Sciences Holdings.Comera Life Sciences, formerly known as ReForm Biologics, was a pharmaceutical technology company focused on developing proprietary excipients to improve biologic formulations.In January 2022, the company changed its name from ReForm Biologics to Comera Life Sciences.In January 2022, Comera Life Sciences entered into a business combination agreement with OTR Acquisition. The transaction was expected to provide Comera with access to the public equity markets and to accelerate the development and advancement of its pipeline subcutaneous (SQ) therapeutics based on SQore formulation platform. The combined company, Comera Life Sciences Holding, was expected to have a combined implied initial pro forma equity value of approximately USD 258.4 million translating into an enterprise value of approximately USD 151.3 million, w